Ticker

Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the first time - measurable reduction in individual patient risk trajectories over 24 months NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today…

Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health. The study of 2,470 patients with type 2 diabetes and early-stage chronic kidney disease was carried out across two US health systems, Mount Sinai in New York and Wake Forest/Atrium Health in…

The novel care model will integrate FDA-approved kidneyintelX.dkd™  and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled…